AbbVie scores FDA nod for Pfizer-partnered antibiotic Emblaveo
Ten months after Pfizer scored approval in Europe for Emblaveo to treat complicated intra-abdominal infections, AbbVie has done the same in the United States, winning an FDA nod for Emblaveo for the same type of Gram-negative infections.
Ten months after Pfizer scored approval in Europe for Emblaveo to treat complicated intra-abdominal infections, AbbVie has done the same in the United States, winning an FDA nod for Emblaveo for the same type of Gram-negative infections.
